RT S.E. Robinson, Jr. (@SERobinsonJr)xAI NEWS: Paul Conyngham, a Sydney-based tech entrepreneur and AI consultant, used Grok to finalize a mRNA vaccine construct for his dog Rosie's mast cell cancer.Paul used three AI models. He combined ChatGPT for initial ideas, AlphaFold for mutation analysis, and Grok took the mutation data and other inputs to create the final sequence for the custom mRNA vaccine targeting those exact mutations.Paul sequenced Rosie's healthy DNA and the tumor DNA for $3,000 at the Unive ...

Core Viewpoint - BioNTech SE plans to establish an independent company led by co-founders Prof. Ugur Sahin and Prof. Özlem Türeci to focus on next-generation mRNA innovations, while BioNTech sharpens its strategic focus on its late-stage clinical pipeline [1][2][5] Group 1: Company Structure and Leadership Transition - The new company will have distinct resources, operations, and funding options to advance mRNA innovations with disruptive potential [1] - Ugur Sahin and Özlem Türeci will transition to the management of the new company by the end of 2026, with BioNTech's Supervisory Board initiating an executive search for their successors [3] - BioNTech plans to contribute related rights and mRNA technologies to the new company in exchange for a minority stake and other forms of consideration such as milestones and royalties [4][5] Group 2: Strategic Focus and Clinical Pipeline - BioNTech is sharpening its strategic focus on the development and commercialization of its late-stage pipeline, which includes innovative immunomodulators, antibody-drug conjugates (ADCs), and mRNA candidates [2][5] - The company expects to have 15 ongoing Phase 3 clinical trials in oncology by the end of 2026, with multiple late-stage data readouts anticipated across major cancer types [2] - The plans for the new company will not affect BioNTech's current clinical pipeline, including its COVID-19 vaccine franchise [2]

Financial Performance - Moderna's revenue surged from approximately $60 million in 2020 to over $19 billion in 2023 due to its mRNA technology and COVID-19 vaccine development [1][3] - However, COVID-related revenue has declined to $1.9 billion, and the company's cash reserves have decreased from over $10 billion to roughly $5.8 billion [4] Product Development - Moderna is currently developing an influenza vaccine that is under review by the FDA, with potential approval before the next flu season [5] - The company is collaborating with Merck on a melanoma therapy, which shows promising trial results but is still in the testing phase [6] Future Outlook - There is caution regarding Moderna's future as it has not yet launched a major new product following its COVID success, leading to elevated spending and stagnant revenue growth [7]

WE ARE COMING ON THE AIR WITH THE DEADLY AVALANCHE IN THE WEST. EIGHT PEOPLE KILLED, SIX SKIERS RESCUED AS A STORM SYSTEM DUMPS SNOW ON THAT STATE, PART OF A DANGEROUS WEATHER PATTERN THREATENING MILLIONS OF PEOPLE. WE'VE GOT TEAM COVERAGE AND A LOOK AT WHAT'S AHEAD.ALSO TONIGHT, THE NEW AND BIGGER REWARD IN TUCSON WITH SO MANY DESPERATELY HOPING FOR ANSWERS ABOUT NANCY GUTHRIE. HOW LAW ENFORCEMENT IS TURNING TO A STRATEGY FOR THEIR NEW DNA EVIDENCE THAT IS PROVEN TO HAVE HELPED BEFORE IN THE CASE OF THE ID ...

This is the last thing, by the way, our parents need when their kids are going back to school is to have the kind of confusion and expense and scarcity that you're creating as a result of your ideology. I think it's critical for you to share the evidence that this panel will rely on. Will you give the American people six months or six weeks in advance the record that they're going to rely on to make these decisions. Will you make it transparent for the American people.>> All the evidence is transparent. >> ...

Funding & Research - The health department is pulling \$500 million (half a billion dollars) in funding specifically for mRNA vaccine development [1] - The terminated contracts are focused on mRNA technology for COVID and flu shots [6] - \$2 million was pulled from a vaccine program for vulnerable children [8] Scientific & Expert Opinions - Experts state mRNA vaccines have been extremely effective against hospitalizations and deaths, even if they don't prevent infections [4] - Scientists and vaccine experts are coming out against the decision to cut mRNA vaccine research, stating it could put people at more risk during public health emergencies [2] - Experts worry about the secretary trying to undermine the US vaccine infrastructure under the guise of safety [8] Potential Risks & Concerns - Concerns exist regarding the potential for the next pandemic and the lack of resources needed to address it [10] - There are long-term concerns about sowing doubt in the safety of vaccines and potentially preventing scientists from developing newer, better vaccines [9]

Industry Focus - The article discusses the potential impact of pulling mRNA vaccine research funding [1] Potential Risks - The article questions whether RFK Jr is correct in his stance regarding mRNA vaccine research funding [1]

The Department of Health and Human Services is winding down its mRNA vaccine development activities. The move includes terminating 22 vaccine investments and canceling and shrinking various contracts and solicitations. https://t.co/GxGGXCF08K ...